Company: SHPH
Filing Date: 2025-03-31
Form Type: DEF 14A
Source: 0001641172-25-001889
Chunk: 15

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-31
Form: DEF 14A
Chunk 15
---
10-K for filing with the SEC.

Respectfully submitted,

The Audit Committee of the Board of Directors

Steve Richards (Chair)

George Scorsis*

Oleh Nabyt*

* Messrs. Scorsis and Nabyt joined as the Company’s Board in February 2025 after the filing of our annual report on Form 10-K for the fiscal year ended December 31, 2024. Accordingly, the Form 10-K mentioned in the above Audit Committee’s report was approved by our previous Audit Committee members. Mr. Richards served as our Audit Committee chair before and after the changes to Audit Committee members.

The immediately preceding report of the Audit Committee does not constitute soliciting material and should not be deemed filed or incorporated by reference into any of previous filings under the Securities Act, or the Exchange Act except to the extent that we specifically incorporate such report by reference.

Vote Required

The Board of Directors recommends a vote “FOR” Proposal No. 2. A majority of the shares present in person or by proxy and entitled to vote at our 2025 Annual Meeting is required to approve Proposal No. 2.

| 13 |

Proposal 3: Advisory Vote on Executive Compensation (“Say on Pay”)

| What                                  
 am I voting on and how should I vote? |     | This                                                                                                                                
 proposal gives our stockholders the opportunity to vote to approve, on an advisory, non-binding                                     
 basis, in accordance with Section 14A of the Exchange Act, the compensation of our Named                                            
 Executive Officers (NEOs), as disclosed in this proxy statement.                                                                    
 The                                                                                                                                 
 Board of Directors therefore recommends you vote “FOR” the resolution that the compensation paid to the Company’s                   
 NEOs, as disclosed pursuant to Item 402 of Regulation S-K, including the Executive Compensation, compensation tables, and narrative 
 discussions to be hereby APPROVED.                                                                                                  |

Approval on an advisory basis of the compensation of our NEOs is an ordinary resolution and must receive the affirmative vote of a majority of the votes cast in person or by proxy at the 2025 Annual Meeting in order to be approved.

THE TEXT OF THE RESOLUTION IN RESPECT OF PROPOSAL 3 IS AS FOLLOWS:

“RESOLVED, that the Company’s stockholders approve, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in this proxy statement in the section entitled “Executive Compensation,” including the compensation tables and narrative discussions